Stoke Therapeutics Hits New 52-Week High at $28.00, Up 80%

Stoke Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 28.00 on October 6, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 1,205 million.
Over the past year, Stoke Therapeutics has demonstrated impressive growth, with a remarkable 80.05% increase in its stock price, significantly outperforming the S&P 500, which recorded a gain of 17.82% during the same period. The company's price-to-earnings (P/E) ratio stands at 12.00, indicating a favorable valuation relative to its earnings.

Stoke Therapeutics maintains a solid return on equity of 15.67%, reflecting its effective management and operational efficiency. Additionally, the company has a price-to-book ratio of 3.60, which provides insight into its market valuation compared to its net assets. With no dividend yield and a negative debt-to-equity ratio of -0.73, Stoke Therapeutics continues to focus on growth and innovation within its industry.